Evidence map›Paper›PMID 39766211›Full record

ArticleBiomolecules2024

Serum EphA2 as a Promising Biomarker for the Early Detection and Diagnosis of Colorectal Cancer.

Shunsuke Sakuraba, Akihiro Koizumi, Takumi Iwasawa, Tomoaki Ito, Kazunori Kato

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomolecules, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Identification ofTranslational cancer research · 2026
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Shunsuke SakurabaDepartment of Surgery, Juntendo University Medical School, Shizuoka Hospital, Shizuoka 410-2295, Japan.
Akihiro KoizumiDepartment of Surgery, Juntendo University Medical School, Shizuoka Hospital, Shizuoka 410-2295, Japan.
Takumi IwasawaShizuoka Medical Research Center for Disaster, Shizuoka 410-2295, Japan.
Tomoaki ItoDepartment of Surgery, Juntendo University Medical School, Shizuoka Hospital, Shizuoka 410-2295, Japan.ORCID 0000-0003-4190-8923
Kazunori KatoInstitute of Life Innovation Studies, Toyo University, Tokyo 115-8650, Japan.

Funding

Japan Society for the Promotion of Science 22H02928 and 23K24189
6 · The paper itself

Abstract

backgroundEphA2, a receptor-type tyrosine kinase, is overexpressed in several cancers, including colorectal cancer (CRC), and can be detected as soluble EphA2 in serum. This study aimed to investigate the relationship between soluble EphA2 and CRC.

methodsSerum samples were collected from 65 patients with CRC and 19 healthy individuals. Time-series changes in soluble EphA2 levels were measured in CRC cell lines to verify the release of EphA2 into the culture medium.

resultsSoluble EphA2 levels were significantly higher in patients than in healthy individuals (

conclusionsThese findings suggest that serum EphA2 could serve as a valuable biomarker for the early detection of CRC, offering a practical and minimally invasive alternative to conventional tumor markers.

Indexed as

Biomarkers, TumorColorectal NeoplasmsEarly Detection of CancerReceptor, EphA2AdultAgedCell Line, TumorFemaleHumansMaleMiddle AgedROC CurveBiomarkers, TumorEPHA2 protein, humanReceptor, EphA2biomarkercolorectal cancerEphA2serum EphA2

Identifiers

PMID39766211
PMCPMC11673381

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.